BOD to Supply for PTSD Study
BOD Australia (ASX: BDA) will be supplying its medicinal...
Research
MGC Pharma publishes results of glioblastoma pre-clinical research
MGC Pharma (ASX: MXC) has published results from a...
Study indicates Medicinal Cannabis improves lives of dementia patients
A study published in the Journal of Medicinal Cannabis...
CannPal’s medicinal cannabis pet product show successful study results
CannPal (ASX: CP1) recently presented Phase I research results...
Canadian study shows Tilray products having positive impact on anxiety
A paper published in the Journal of Psychiatric Research...
Study shows CBD reduces seizures by almost 50%
More evidence has been found on the therapeutic use...
Tilray expands clinical research support
Tilray (NASDAQ: TLRY) has announced the support of two...
MGC Pharma delivers update on R&D and commercial strategy
MGC Pharmaceuticals (ASX: MXC, OTC: MGCLF) has released an...
BOD completes Phase I on medicinal cannabis wafer
The trial shows the product is safe for human use.
Impression Healthcare goes deep on clinical research.
The partnership is for medicinal cannabis research and commercialisation.
Page 1 of 2